Korro Bio (KRRO) Projected to Post Earnings on Wednesday

Key Points

• Korro Bio is expected to report Q3 2026 results on November 11. Analysts forecast a loss of $1.26 per share and revenue of $0.19 million; the earnings call is scheduled for November 13 at 9:30 a.m. ET.
• The company’s previous quarter loss of $1.07 per share was narrower than analysts’ $1.34 estimate. Analysts expect losses of $4.95 per share for the current fiscal year and $4.46 next year.
• Analysts’ consensus rating is Moderate Buy, with an average price target of $16.50. Over the past 90 days, insiders purchased about 86,500 shares and sold about 38,300.

Korro Bio (NASDAQ:KRRO - Get Free Report) is expected to release its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to post earnings of ($1.2619) per share and revenue of $0.19 million for the quarter. Individuals may visit the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Korro Bio (NASDAQ:KRRO - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($1.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.34) by $0.27. On average, analysts expect Korro Bio to post ($4.95) EPS for the current fiscal year and ($4.46) EPS for the next fiscal year.

Korro Bio Trading Up 0.1%

Shares of NASDAQ:KRRO opened at $15.86 on Wednesday. The business's 50-day simple moving average is $11.51 and its 200 day simple moving average is $11.96. Korro Bio has a one year low of $5.20 and a one year high of $38.42.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Korro Bio in a research report on Tuesday, October 6th. Wall Street Zen raised shares of Korro Bio from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 8th. Jefferies Financial Group set a $15.00 target price on shares of Korro Bio in a research note on Tuesday, October 6th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Korro Bio in a report on Friday, October 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Korro Bio presently has an average rating of "Moderate Buy" and a consensus target price of $16.50.

Insider Buying and Selling

In other Korro Bio news, major shareholder Lynx1 Capital Management Lp acquired 52,175 shares of the company's stock in a transaction on Thursday, October 22nd. The shares were bought at an average cost of $10.72 per share, for a total transaction of $559,316.00. Following the acquisition, the insider directly owned 1,597,155 shares of the company's stock, valued at $17,121,501.60. This trade represents a 3.38% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jean Formela sold 28,468 shares of the company's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $14.00, for a total value of $398,552.00. Following the completion of the transaction, the director directly owned 141,053 shares in the company, valued at approximately $1,974,742. The trade was a 16.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have acquired 86,493 shares of company stock worth $963,734 and have sold 38,269 shares worth $532,064. Insiders own 4.80% of the company's stock.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company developing RNA editing medicines for genetically driven diseases. The company's approach is designed to make targeted changes to messenger RNA, potentially correcting or altering disease-related genetic instructions without permanently changing a patient's DNA.

Korro Bio's technology platform uses programmable oligonucleotides to guide RNA editing in specific cells and tissues. Its lead development program, KRRO-110, is being developed for alpha-1 antitrypsin deficiency, an inherited disorder caused by mutations in the SERPINA1 gene that can lead to liver and lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.